News Search

Category: Schools

New Mini-documentary Showcases the Path to CAR-T Cell Therapy  

This short documentary tells the powerful story of Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at Penn Medicine, and the successful use of CAR-T cell therapy.

Penn Engineering Faculty Attend AI & Energy Summit in Pittsburgh   

Penn Engineering faculty showcased Penn research, technologies, and start-up companies in the fields of energy, AI and computing.

Penn Medicine Highlights Public Funding’s Role in Translating Scientific Discoveries into Life-Saving Treatments  

Stephen Bagley, MD, MSCE, Assistant Professor of Hematology-Oncology and Neurosurgery at Penn Medicine, discusses how he used CAR T cell therapy to shrink a patient's tumor.

Nicholas Siciliano, Chief Executive Officer and Co-Founder of Penn Spinout ViTToria Biotherapeutics, Wins the Science Center’s 2025 Commercialization Award  

Siciliano won the Science Center’s 2025 Commercialization Award in recognition of his outstanding contributions to the commercialization of innovative science and technology. 

Avisi Technologies Present Promising Clinical Data at the American Glaucoma Society  

Avisi is based on technology invented by Igor Bargatin, PhD, Associate Professor of Mechanical Engineering and Applied Mechanics at Penn Engineering.

Apellis’ Empaveli® Gains FDA Approval for Broader Rare Kidney Disease Use  

Penn spinout Apellis received FDA approval for an expanded label for Empaveli®.

Carisma Therapeutics Enters into Definitive Merger Agreement with OrthoCellix to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases  

Carisma Therapeutics, co-founded by Saar Gill, MD, PhD, Associate Professor of Medicine at Penn Medicine, is merging with OrthoCellix.

Penn Spinout Dispatch Bio Emerges from Stealth Mode with $216M in Funding   

Dispatch Bio, co-founded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine, is developing a universal cancer treatment for solid tumors.

Penn Spinout Interius Therapeutics To Be Acquired by Kite Therapeutics for $350M

Kite Therapeutics, a Gilead Company, has entered into a definitive agreement to acquire Interius Therapeutics .

Filter

Skip to content